GlassScriptPhysician profile
Tommy E Price
NPI 1508435298
$15,126.82
in general payments reported to CMS, 2019-2025
66 companies · $4,182 in 2025
The $4,182 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $791 · 2022: $2,653 · 2023: $3,552 · 2024: $3,950 · 2025: $4,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $706 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,678.34 |
| Education | $705.92 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,264.52 | 2022-2025 | Rybrevant, Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $1,194.72 | 2022-2025 | |
| Celgene Corporation | $1,007.83 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $990.44 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Incyte Corporation | $932.16 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $917.57 | 2021-2025 | Opdivo, Opdualag |
| Amgen INC. | $604.85 | 2021-2023 | Lumakras, Repatha, Nplate |
| Bayer Healthcare Pharmaceuticals INC. | $584.01 | 2021-2025 | |
| Pfizer INC. | $570.35 | 2021-2025 | |
| Daiichi Sankyo INC. | $560.44 | 2022-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $495.21 | 2022-2025 | Xtandi, Padcev, Vyloy |
| Seagen INC. | $482.16 | 2021-2023 | Padcev, Adcetris, Tukysa |
| Ipsen Biopharmaceuticals, INC | $395.22 | 2021-2025 | Onivyde |
| Merck Sharp & Dohme LLC | $345.35 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $337.67 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tommy Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.